Profile data is unavailable for this security.
About the company
Lupin Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept. It diabetes brands include ONDERO and ONDERO MET.
- Revenue in INR (TTM)194.80bn
- Net income in INR17.91bn
- Incorporated1983
- Employees18.97k
- LocationLupin LtdB/4 Laxmi Towers, Bandra Kurla Complex, Bandra (E)MUMBAI 400055IndiaIND
- Phone+91 2 266402323
- Fax+91 2 266402051
- Websitehttps://www.lupin.com/
Mergers & acquisitions
| Acquired company | LUPIN:NSI since announced | Transaction value |
|---|---|---|
| A Menarini India Pvt Ltd | 44.08% | 12.15m |
| A Menarini Asia-Pacific Holdings Pte Ltd | 44.08% | -- |
| Medisol SAS | 128.40% | 19.82m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 566.16bn | 16.87k | 35.99 | -- | 30.29 | 4.48 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 278.95bn | 27.70bn | 637.76bn | 15.69k | 23.04 | -- | 14.90 | 2.29 | 47.25 | 47.25 | 475.59 | -- | -- | -- | -- | 17,778,640.00 | -- | 9.84 | -- | 14.92 | 55.29 | 53.05 | 9.92 | 13.06 | -- | 23.89 | -- | 8.33 | 5.97 | 8.54 | -27.21 | -4.47 | 12.20 | 3.71 |
| Lupin Ltd | 194.80bn | 17.91bn | 739.24bn | 18.97k | 41.40 | -- | 26.28 | 3.79 | 39.19 | 39.19 | 426.18 | -- | -- | -- | -- | 10,268,360.00 | -- | 0.2337 | -- | 0.3443 | 64.99 | 58.56 | 9.29 | 0.3673 | -- | 6.89 | -- | 470.26 | 1.44 | 1.04 | 128.15 | 11.35 | -0.7025 | -4.36 |
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 872.41bn | 13.57k | 58.00 | -- | 37.94 | 8.33 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Mankind Pharma Ltd | 99.46bn | 17.27bn | 929.51bn | 18.47k | 53.86 | -- | 43.50 | 9.35 | 43.08 | 43.08 | 248.12 | -- | -- | -- | -- | 5,385,717.00 | -- | -- | -- | -- | 68.37 | -- | 17.68 | -- | -- | 144.35 | -- | -- | 12.44 | -- | -10.58 | -- | -- | -- |
| Zydus Lifesciences Ltd | 186.81bn | 29.56bn | 968.15bn | 23.03k | 32.94 | -- | 26.23 | 5.18 | 29.21 | 29.38 | 184.58 | -- | -- | -- | -- | 8,113,133.00 | -- | 7.92 | -- | 12.61 | 66.21 | 60.14 | 15.81 | 12.89 | -- | -- | -- | 20.55 | 14.08 | 7.59 | -12.34 | 1.83 | -0.3532 | 11.38 |
| Divi's Laboratories Ltd | 74.93bn | 13.83bn | 1.00tn | 16.95k | 72.54 | -- | 57.24 | 13.39 | 52.11 | 52.11 | 282.31 | -- | -- | -- | -- | 4,420,514.00 | -- | 18.50 | -- | 20.48 | 59.23 | 57.21 | 18.46 | 27.90 | -- | -- | -- | 31.31 | -13.31 | 14.70 | -38.41 | 15.76 | 11.55 | 24.57 |
| Dr Reddy's Laboratories Ltd | 272.13bn | 52.28bn | 1.01tn | 24.83k | 19.39 | -- | 15.24 | 3.72 | 313.75 | 313.75 | 1,633.13 | -- | -- | -- | -- | 10,958,640.00 | -- | 9.68 | -- | 13.81 | 70.55 | 65.53 | 19.21 | 12.76 | -- | 48.92 | -- | 17.84 | 14.50 | 11.55 | 106.94 | 33.23 | 11.31 | 14.87 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 37.49m | 8.23% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2023 | 23.39m | 5.13% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2023 | 16.73m | 3.67% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 9.37m | 2.06% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 8.53m | 1.87% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Sep 2023 | 7.66m | 1.68% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Sep 2023 | 7.66m | 1.68% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 6.27m | 1.38% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 6.12m | 1.34% |
| SBI Funds Management Ltd.as of 31 Mar 2024 | 5.22m | 1.15% |
